Sage Journals: Discover world-class research

Abstract

Keywords

Alemtuzumab infection safety immunosuppression risk management

Get full access to this article

View all access options for this article.

References

Russo

Saccà

Paternoster

, et al. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler 2020; 26: 123–126.

Buonomo

Zappulo

Viceconte

, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018; 17(7): 709–717.

Coles

Robertson

Al-Araji

, et al. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis, 2018, https://www.theabn.org/media/Guidance%20on%20the%20prevention%20of%20Listeria%20infection%20after%20alemtuzumab%20treatment%20of%20multiple%20sclerosis.pdf

Grulich

vanLeeuwen

Falster

, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370(9581): 59–67.

Clinical commentary on ‘Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis’

Abstract

Keywords

Get full access to this article

References